The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

Work +1 212 335 4500
Fax +1 212 335 4501

Loren Brown

Work +1 212 335 4846
DLA Piper LLP (US)

Work Department

Product Liability, Mass Torts and Product Stewardship


Partner, Global Co-Chair of DLA Piper's Litigation Practice, and Co-Chair of DLA Piper's US Litigation Practice


Loren has an extensive litigation practice with a concentration in multi-district litigation that often involves large-scale mass tort and class action matters, as well as parallel regulatory and government enforcement proceedings. Loren's business litigation practice includes a range of commercial tort and contract, trade secret, intellectual property and securities class action matters. Loren also has significant experience in a range of internal investigation, compliance, and regulatory matters, particularly within the life sciences sector.

Loren also regularly counsels clients on a wide-range of regulatory, risk management, due-diligence, product labeling, product recall, public disclosure, policy and crisis-management issues.


JD, Hofstra University; BS, University of Maryland

United States: Dispute resolution

Product liability, mass tort and class action: pharmaceuticals and medical devices - defense

Within: Leading lawyers

Loren Brown - DLA Piper LLP (US)

Within: Product liability, mass tort and class action: pharmaceuticals and medical devices - defense

DLA Piper LLP (US)’s pharmaceutical and medical device practice is jointly headed by Raymond Williams in Philadelphia and Christopher Young in San Diego, and handles sector-related product liability litigation and mass torts. Williams and New York-based Loren Brown continue to act as national counsel for Novo Nordisk in all litigation arising from claims alleging that some type 2 diabetes treatments can cause pancreatic cancer and pancreatitis. In other ongoing work, Brown defends Pfizer in product liability litigation, in which plaintiffs claim that long-term use of proton pump inhibitors (PPIs) cause various forms of kidney disease. Together with Boston-based Matthew Holian, Brown also represents Bristol-Myers Squibb and Pfizer in an MDL involving claims that anticoagulant medication Eliquis causes bleeding. Bayer, Medtronic and Biogen are also clients of the firm. Cara Edwards in New York is another name to note and Boston-based Jessica Wilson was invited to partnership in January 2017.

[back to top]

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

DLA Piper LLP (US)’s ‘excellent, responsive and knowledgeable’ department has considerable experience assisting high-profile clients with regulatory, transactional and IP matters, as well as complex global disputes. San Diego-based co-head Lisa Haile and New York-based Stuart Pollack have been leading advice to SteadyMed on various patent invalidation claims brought against United Therapeutics before the Patent Trial and Appeal Board (PTAB). Co-head Richard Mulloy and Drew Wintringham, who are in San Diego and New York, respectively, have been representing Covidien in patent litigation brought against Ethicon arising from the release of Ethicon’s Enseal X1 medical device. The team also acted for Sanpower Group on its $820m acquisition of Dendreon Pharmaceuticals. Also led by product liability expert Matthew Holian in Boston, the team includes George Karavetsos in Miami, Loren Brown in New York, Raymond Williams in Philadelphia, Larry Nishnick in San Diego and Aaron Fountain, who splits his time between Austin and Houston.

[back to top]

Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to